Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TAS3681 |
Synonyms | |
Therapy Description |
TAS3681 is an androgen receptor (AR) inhibitor that induces cell death in AR-positive prostate cancer cells, potentially resulting in antitumor activity (J Clin Oncol 33, 2015 (suppl 7; abstr 266); J Clin Oncol 39, no. 15_suppl (May 20, 2021) 5031-5031). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TAS3681 | TAS 3681 | Hormone - Anti-androgens 54 | TAS3681 is an androgen receptor (AR) inhibitor that induces cell death in AR-positive prostate cancer cells, potentially resulting in antitumor activity (J Clin Oncol 33, 2015 (suppl 7; abstr 266); J Clin Oncol 39, no. 15_suppl (May 20, 2021) 5031-5031). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02566772 | Phase I | TAS3681 | Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer | Completed | USA | GBR | FRA | ESP | 0 |